Pediatric AML survival in Uruguay remains below international benchmarks, mainly due to treatment-related mortality during induction. Implementation of CHIP-AML22, together with stronger induction management and supportive care, offers opportunities to improve survival and narrow this gap.
Dapueto et al. (Sat,) studied this question.